Plus Therapeutics, Inc.
PSTV
$0.7691
-$0.075-8.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.82M | 5.73M | 5.51M | 6.08M | 4.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.82M | 5.73M | 5.51M | 6.08M | 4.91M |
| Cost of Revenue | 10.58M | 11.19M | 10.82M | 9.47M | 9.69M |
| Gross Profit | -4.76M | -5.46M | -5.31M | -3.39M | -4.78M |
| SG&A Expenses | 9.94M | 9.19M | 8.79M | 8.51M | 8.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.52M | 20.38M | 19.61M | 17.98M | 18.23M |
| Operating Income | -14.70M | -14.65M | -14.11M | -11.90M | -13.32M |
| Income Before Tax | -12.98M | -12.89M | -13.23M | -11.77M | -13.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.98 | -12.89 | -13.23 | -11.77 | -13.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.98M | -12.89M | -13.23M | -11.77M | -13.32M |
| EBIT | -14.70M | -14.65M | -14.11M | -11.90M | -13.32M |
| EBITDA | -13.97M | -13.98M | -13.47M | -11.27M | -12.69M |
| EPS Basic | -2.07 | -2.42 | -3.05 | -3.19 | -4.51 |
| Normalized Basic EPS | -1.29 | -1.51 | -1.91 | -1.99 | -2.82 |
| EPS Diluted | -2.33 | -2.68 | -3.31 | -3.19 | -4.51 |
| Normalized Diluted EPS | -1.18 | -1.40 | -1.80 | -1.99 | -2.82 |
| Average Basic Shares Outstanding | 26.54M | 23.18M | 18.55M | 14.56M | 12.55M |
| Average Diluted Shares Outstanding | 30.79M | 27.42M | 22.79M | 14.56M | 12.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |